biotech · Acute Respiratory Distress Syndrome (ARDS) · Allergic Contact Dermatitis · EDSA
Edesa Biotech
Edesa Biotech clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Markham, CA
- Founded
- 2015
- Employees
- 22
- Programs
- 5
- Drugs
- 5
- Patents
- 0
Edesa Biotech projects
5 ClinicalTrials.gov programs sponsored by Edesa Biotech.
Edesa Biotech has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
SOC plus 15mg/kg EB05 IV
Edesa Biotech
COVID-19
1 trial -
Cohort A: vilobelimab
Edesa Biotech
Acute Respiratory Distress Syndrome (ARDS)
2 trials -
Cohort B: paridiprubart
Edesa Biotech
Acute Respiratory Distress Syndrome (ARDS)
1 trial -
Cohort C: bevacizumab
Edesa Biotech
Acute Respiratory Distress Syndrome (ARDS)
1 trial -
EB01 Cream Placebo
Edesa Biotech
Allergic Contact Dermatitis
1 trial
Frequently asked questions
How many clinical projects does Edesa Biotech have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.